January 13, 2021 07:08 AM ESTUpdated 09:34 AM
FDA+

Bay­er wins pri­or­i­ty re­view for CKD pro­gram finerenone af­ter PhI­II da­ta showed a de­lay in dis­ease pro­gres­sion

Max Gelman

Senior Editor

Less than three months af­ter Bay­er re­leased pos­i­tive Phase III da­ta for a top pro­gram, the FDA has agreed to take up its case. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times